A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients

被引：0
|
作者：
Haeberle, L. [1 ]
Erber, R. [2 ]
Gass, P. [1 ]
Hein, A. [1 ]
Jud, S. M. [1 ]
Langemann, H. [1 ]
Rauh, C. [1 ]
Hack, C. C. [1 ]
Schulz-Wendtland, R. [3 ]
Hartmann, A. [2 ]
Beckmann, M. W. [1 ]
Lux, M. P. [1 ]
Fasching, P. A. [1 ]
机构：
[1] Erlangen Univ Hosp, Dept Gynecol & Obstet, Erlangen, Germany
[2] Erlangen Univ Hosp, Inst Pathol, Erlangen, Germany
[3] Erlangen Univ Hosp, Inst Radiol, Erlangen, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
226P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
    Ishikawa, Takashi
    Akazawa, Kouhei
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Hayashi, Mitsuhiro
    Kohno, Norio
    JOURNAL OF SURGICAL RESEARCH, 2017, 220 : 46 - 51
  • [42] Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
    Tang, Lingfeng
    Shu, Xiujie
    Tu, Gang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [43] Exploring the influencing factors of the pathologic complete response in estrogen receptor-positive, HER2-negative breast cancer after neoadjuvant chemotherapy: a retrospective study
    Lingfeng Tang
    Xiujie Shu
    Gang Tu
    World Journal of Surgical Oncology, 20
  • [44] Studies on factors for pathological complete response after neoadjuvant chemotherapy in relation to HER2 status in primary breast cancer
    Arima, Nobuyuki
    Nishimura, Reiki
    Muramoto, Kazuhiro
    Inayoshi, Atsushi
    Tanigawa, Tomio
    Watanabe, Sugiko
    CANCER RESEARCH, 2024, 84 (09)
  • [45] Clinicopathological factors for predicting tumor response in hormonal positive/HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
    Yincharoen, P.
    Samarnthai, N.
    Korphaisarn, K.
    Imruetaicharoenchoke, W.
    BREAST, 2023, 68 : S57 - S57
  • [46] Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
    Arqueros, Cristina
    Salazar, Juliana
    Gallardo, Alberto
    Andres, Marta
    Tibau, Ariadna
    Bell, Olga Lidia
    Artigas, Alicia
    Lasa, Adriana
    Cajal, Teresa
    Lerma, Enrique
    Barnadas, Agusti
    BIOMEDICINES, 2023, 11 (12)
  • [47] Tumor-Stroma Ratio Is Associated with Miller-Payne and Pathological Response to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer
    Hagenaars, Sophie C.
    de Groot, Stefanie
    Cohen, Danielle
    Dekker, Tim J. A.
    Charehbili, Ayoub
    Kranenbarg, Elma Meershoek-Klein
    Duijm-de Carpentier, Marjolijn
    Pijl, Hanno
    Putter, Hein
    Tollenaar, Rob A. E. M.
    Kroep, Judith R.
    Mesker, Wilma E.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S146 - S147
  • [48] Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
    Shi, Yue
    Lu, Heng
    Zhang, Yiqi
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 206 (02) : 387 - 395
  • [49] Tumor-stroma ratio is associated with Miller-Payne and pathological response to neoadjuvant chemotherapy in HER2-negative early breast cancer
    Hagenaars, S.
    de Groot, S.
    Cohen, D.
    Charehbili, A.
    Dekker, T.
    Kranenbarg, E. Meershoek-Klein
    Duijm-de Carpentier, M.
    Pijl, H.
    Putter, H.
    Tollenaar, R.
    Kroep, J.
    Mesker, W.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S106 - S106
  • [50] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
12345